I used this fund right after the economy went south in late 2008. It has been superb. And the dividends multiply like rabbits. I will stay the course.
This product was innovative years ago when it came out: biomaterial, non-invasive, and easy to administer. It is temporary b/c the collagen is absorbed and you need to get repeated injections. Bard thought the re-occuring revenue would be a windfall, patients thought otherwise. So... they bought a start up years ago (1997) which would be a permanent solution. They did nothing with it. Why? That is what I want to know? As for a new supplier of collagen, yes very possible.